IC43

BIOLOGICAL3 trials

Sponsors

Valneva Austria GmbH

Conditions

HealthyPneumonia, Ventilator-AssociatedPseudomonas Aeruginosa Infection

Phase 1

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

CompletedNCT00778388

Valneva Austria GmbHHealthy

Start: 2008-09-30End: 2009-09-30Updated: 2012-10-19

Phase 2

Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

CompletedNCT00876252

Valneva Austria GmbHPneumonia, Ventilator-Associated

Start: 2008-12-31End: 2010-02-28Updated: 2012-10-19

Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

CompletedNCT01563263

Valneva Austria GmbHPseudomonas Aeruginosa Infection

Start: 2012-03-31End: 2015-12-31Updated: 2016-03-31

Related Papers

Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.

2020-03-0452 citations

A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Critical Care2017-02-0375 citations